Biohaven pauses new U.S. enrollment after FDA partial clinical hold
Biohaven paused new U.S. patient enrollment in its BHV-7000 program after an FDA partial clinical hold. Dosing continues for already randomized patients.
Biohaven paused new U.S. patient enrollment in its BHV-7000 program after an FDA partial clinical hold while dosing continues for already randomized patients.Key Highlights:Original SEC Filing: Biohaven Ltd. [ BHVN ] - 8-K - Sep. 09, 2026This is an AI-powered summary.
It may contain inaccuracies. C…